tela bio inc - TELA

TELA

Close Chg Chg %
0.95 -0.01 -1.06%

Open Market

0.94

-0.01 (1.06%)

Volume: 60.04K

Last Updated:

May 21, 2026, 1:31 PM EDT

Company Overview: tela bio inc - TELA

TELA Key Data

Open

$0.97

Day Range

0.91 - 0.98

52 Week Range

0.50 - 2.20

Market Cap

$42.53M

Shares Outstanding

44.77M

Public Float

32.57M

Beta

1.30

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.80

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

253.45K

 

TELA Performance

1 Week
 
4.86%
 
1 Month
 
41.64%
 
3 Months
 
32.28%
 
1 Year
 
-34.10%
 
5 Years
 
-92.84%
 

TELA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About tela bio inc - TELA

TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.

TELA At a Glance

TELA Bio, Inc.
1 Great Valley Parkway
Malvern, Pennsylvania 19355
Phone 1-484-320-2930 Revenue 80.28M
Industry Medical Specialties Net Income -38,831,000.00
Sector Health Technology 2025 Sales Growth 15.837%
Fiscal Year-end 12 / 2026 Employees 218
View SEC Filings

TELA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.69
Price to Book Ratio 8.325
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.90
Enterprise Value to Sales 0.775
Total Debt to Enterprise Value 0.927

TELA Efficiency

Revenue/Employee 368,233.945
Income Per Employee -178,123.853
Receivables Turnover 6.719
Total Asset Turnover 0.948

TELA Liquidity

Current Ratio 4.205
Quick Ratio 3.592
Cash Ratio 2.829

TELA Profitability

Gross Margin 67.694
Operating Margin -42.049
Pretax Margin -48.086
Net Margin -48.372
Return on Assets -45.858
Return on Equity -223.353
Return on Total Capital -60.705
Return on Invested Capital -57.778

TELA Capital Structure

Total Debt to Total Equity 913.258
Total Debt to Total Capital 90.131
Total Debt to Total Assets 70.287
Long-Term Debt to Equity 904.958
Long-Term Debt to Total Capital 89.312
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Tela Bio Inc - TELA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
41.42M 58.45M 69.30M 80.28M
Sales Growth
+40.58% +41.13% +18.56% +15.84%
Cost of Goods Sold (COGS) incl D&A
14.37M 18.34M 22.81M 25.93M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.19M 808.00K 1.01M 1.01M
Depreciation
383.00K 428.00K 632.00K 630.00K
Amortization of Intangibles
804.00K 380.00K 380.00K 380.00K
COGS Growth
+34.97% +27.60% +24.38% +13.69%
Gross Income
27.04M 40.11M 46.49M 54.34M
Gross Income Growth
+43.75% +48.32% +15.90% +16.89%
Gross Profit Margin
+65.30% +68.62% +67.08% +67.69%
2022 2023 2024 2025 5-year trend
SG&A Expense
66.05M 84.19M 88.18M 88.10M
Research & Development
8.94M 9.62M 8.81M 9.22M
Other SG&A
57.11M 74.57M 79.37M 78.88M
SGA Growth
+36.85% +27.46% +4.75% -0.10%
Other Operating Expense
- - - -
-
Unusual Expense
- - 1.23M 888.00K
-
EBIT after Unusual Expense
(40.23M) (44.08M) (41.70M) (34.64M)
Non Operating Income/Expense
(10.00K) 2.63M 9.00M 1.29M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.05M 5.22M 5.29M 5.25M
Interest Expense Growth
+12.62% +28.93% +1.28% -0.85%
Gross Interest Expense
4.05M 5.22M 5.29M 5.25M
Interest Capitalized
- - - -
-
Pretax Income
(44.30M) (46.66M) (37.98M) (38.60M)
Pretax Income Growth
-33.12% -5.35% +18.60% -1.62%
Pretax Margin
-106.95% -79.83% -54.81% -48.09%
Income Tax
- - (144.00K) 230.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - 86.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - 144.00K
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(44.30M) (46.66M) (37.84M) (38.83M)
Minority Interest Expense
- - - -
-
Net Income
(44.30M) (46.66M) (37.84M) (38.83M)
Net Income Growth
-33.12% -5.35% +18.91% -2.62%
Net Margin Growth
-106.95% -79.83% -54.60% -48.37%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(44.30M) (46.66M) (37.84M) (38.83M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(44.30M) (46.66M) (37.84M) (38.83M)
EPS (Basic)
-2.723 -2.0405 -1.3265 -0.8271
EPS (Basic) Growth
-18.44% +25.06% +34.99% +37.65%
Basic Shares Outstanding
16.27M 22.87M 28.53M 46.95M
EPS (Diluted)
-2.723 -2.0405 -1.3265 -0.8271
EPS (Diluted) Growth
-18.44% +25.06% +34.99% +37.65%
Diluted Shares Outstanding
16.27M 22.87M 28.53M 46.95M
EBITDA
(37.82M) (43.27M) (40.68M) (32.74M)
EBITDA Growth
-30.79% -14.40% +5.97% +19.51%
EBITDA Margin
-91.31% -74.02% -58.71% -40.79%

Snapshot

Average Recommendation BUY Average Target Price 3.45
Number of Ratings 5 Current Quarters Estimate -0.174
FY Report Date 06 / 2026 Current Year's Estimate -0.654
Last Quarter’s Earnings -0.21 Median PE on CY Estimate N/A
Year Ago Earnings -0.83 Next Fiscal Year Estimate -0.538
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.17 -0.15 -0.65 -0.54
High Estimates -0.15 -0.13 -0.59 -0.45
Low Estimate -0.20 -0.16 -0.69 -0.63
Coefficient of Variance -11.65 -8.05 -7.04 -14.03

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Tela Bio Inc in the News